You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Biogen Idec reports 4Q revenue rise of 7 percent

Biogen Idec Inc., a Weston company known for its multiple sclerosis drugs such as Avonex and Tysabri, said Monday that its fourth-quarter revenues rose 7 percent on a year-to-year basis to $1.4 billion.

Fourth-quarter 2012 GAAP diluted earnings per share were $1.23, an increase of 1 percent over the fourth quarter of 2011. GAAP net income attributable to Biogen Idec for the quarter was $292 million, a decrease of 3 percent from the fourth quarter of 2011.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week